Defymed's mission is to develop innovative medical devices for diabetic patients providing effective treatments and improving quality of life
million diabetics worldwide forecasted for 2045
billion per year spent on diabetes-related expenses
more than 10
million diabetics receiving insulin therapy have poorly regulated blood glucose levels
April 25 2018
Strasbourg, FRANCE, April 2018, Medical device developer Defymed announced today the signing of a me...
February 13 2018
Strasbourg, France, February 2018 – French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices – ExOlin®, an insulin delivery device, and MailPan®, a bioartificial pancreas – the company intends to strengthen its position as a worldwide leader in innovative phys...